FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080883445> ?p ?o ?g. }

• W2080883445 endingPage "514" @default.
• W2080883445 startingPage "507" @default.
• W2080883445 abstract "Genetic alterations for targeting therapy are largely unexplored issues in pulmonary sarcomatoid carcinoma (PSC), a life-threatening tumor subset.EGFR, HER2, KRAS, p53, CTNNB1, BRAF and PIK3CA mutations were assessed by direct sequencing, ALK, EGFR and HER2 gene status by fluorescence in situ hybridization (FISH), and ALK protein expression by immunohistochemistry (IHC) in 20 pleomorphic carcinomas (PLC), two pulmonary blastomas (PB) and one carcinosarcoma (CS). Surgical specimens and, in case of positivity, the corresponding preoperative biopsies were analyzed. Furthermore, 51 consecutive metastatic lung adenocarcinomas (MELAD) were used as controls for FISH and IHC assays of ALK gene.While no rearrangements of ALK were detected in PSC, relevant amplification was identified 5/23 (22%) surgical specimens and paired biopsies (four PLC and one PB, two females and three males, four current and one never smoker, aged 30-83 years). Considering tumor heterogeneity, the percentage of ALK amplified tumor cells ranged from 11% to 43%, with a mean gene copy gain (GCG ± SD) of 6.9 ± 0.8 and no signal differences between the epithelial (6.5 ± 0.9) and the sarcoma-like components (6.8 ± 0.9) of tumors. In the remaining 18 non-amplified PSC, the relevant value was 2.9 ± 0.5 in 1-80% tumor cells (p<0.001). ALK amplification was closely associated with chromosome 7 (EGFR) or 17 (HER2) polysomy (p<0.001). Out of 51 MELAD, 10 were ALK-rearranged (p=0.026) and only one amplified (p=0.009). No amplified tumors, either PSC or MELAD, expressed the relevant protein by IHC, while the 10 ALK-rearranged MELAD were strongly positive. TP53, KRAS and CTNNB1 mutations accounted for 30%, 22%, and 4% of cases, respectively, with no significant relationship with ALK amplification. No mutations for EGFR, HER2, BRAF or PIK3CA gene were observed.ALK gene amplification is a nonrandom and clonally related event in a subset of PSC, but its biologic rationale deserves further investigation. KRAS mutation could represent a novel tool for therapy of such so deadly tumors with MEK inhibitors." @default.
• W2080883445 created "2016-06-24" @default.
• W2080883445 creator A5012846839 @default.
• W2080883445 creator A5015740152 @default.
• W2080883445 creator A5024763432 @default.
• W2080883445 creator A5026006211 @default.
• W2080883445 creator A5026308303 @default.
• W2080883445 creator A5027141635 @default.
• W2080883445 creator A5030828453 @default.
• W2080883445 creator A5039259142 @default.
• W2080883445 creator A5039981930 @default.
• W2080883445 creator A5045629779 @default.
• W2080883445 creator A5048676751 @default.
• W2080883445 creator A5050558965 @default.
• W2080883445 creator A5051378203 @default.
• W2080883445 creator A5052353123 @default.
• W2080883445 creator A5067077344 @default.
• W2080883445 creator A5081257602 @default.
• W2080883445 creator A5081649988 @default.
• W2080883445 creator A5087649056 @default.
• W2080883445 date "2012-09-01" @default.
• W2080883445 modified "2023-10-12" @default.
• W2080883445 title "Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene" @default.
• W2080883445 cites W1517005017 @default.
• W2080883445 cites W1980497534 @default.
• W2080883445 cites W1988442083 @default.
• W2080883445 cites W2002380615 @default.
• W2080883445 cites W2019320906 @default.
• W2080883445 cites W2024772577 @default.
• W2080883445 cites W2028770753 @default.
• W2080883445 cites W2029218729 @default.
• W2080883445 cites W2031034417 @default.
• W2080883445 cites W2045153451 @default.
• W2080883445 cites W2046900244 @default.
• W2080883445 cites W2060230558 @default.
• W2080883445 cites W2064997783 @default.
• W2080883445 cites W2065505515 @default.
• W2080883445 cites W2071854297 @default.
• W2080883445 cites W2075093296 @default.
• W2080883445 cites W2075710933 @default.
• W2080883445 cites W2076209261 @default.
• W2080883445 cites W2076688179 @default.
• W2080883445 cites W2085578045 @default.
• W2080883445 cites W2093895424 @default.
• W2080883445 cites W2098455835 @default.
• W2080883445 cites W2100022068 @default.
• W2080883445 cites W2103894337 @default.
• W2080883445 cites W2104830962 @default.
• W2080883445 cites W2107426358 @default.
• W2080883445 cites W2109956432 @default.
• W2080883445 cites W2115833310 @default.
• W2080883445 cites W2123447042 @default.
• W2080883445 cites W2134820929 @default.
• W2080883445 cites W2139110945 @default.
• W2080883445 cites W2143171062 @default.
• W2080883445 cites W2153345506 @default.
• W2080883445 cites W2249946566 @default.
• W2080883445 cites W2312504937 @default.
• W2080883445 cites W2327437619 @default.
• W2080883445 cites W2410562408 @default.
• W2080883445 cites W4384455562 @default.
• W2080883445 doi "https://doi.org/10.1016/j.lungcan.2012.05.093" @default.
• W2080883445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22705117" @default.
• W2080883445 hasPublicationYear "2012" @default.
• W2080883445 type Work @default.
• W2080883445 sameAs 2080883445 @default.
• W2080883445 citedByCount "64" @default.
• W2080883445 countsByYear W20808834452012 @default.
• W2080883445 countsByYear W20808834452013 @default.
• W2080883445 countsByYear W20808834452014 @default.
• W2080883445 countsByYear W20808834452015 @default.
• W2080883445 countsByYear W20808834452016 @default.
• W2080883445 countsByYear W20808834452017 @default.
• W2080883445 countsByYear W20808834452018 @default.
• W2080883445 countsByYear W20808834452019 @default.
• W2080883445 countsByYear W20808834452020 @default.
• W2080883445 countsByYear W20808834452021 @default.
• W2080883445 countsByYear W20808834452022 @default.
• W2080883445 countsByYear W20808834452023 @default.
• W2080883445 crossrefType "journal-article" @default.
• W2080883445 hasAuthorship W2080883445A5012846839 @default.
• W2080883445 hasAuthorship W2080883445A5015740152 @default.
• W2080883445 hasAuthorship W2080883445A5024763432 @default.
• W2080883445 hasAuthorship W2080883445A5026006211 @default.
• W2080883445 hasAuthorship W2080883445A5026308303 @default.
• W2080883445 hasAuthorship W2080883445A5027141635 @default.
• W2080883445 hasAuthorship W2080883445A5030828453 @default.
• W2080883445 hasAuthorship W2080883445A5039259142 @default.
• W2080883445 hasAuthorship W2080883445A5039981930 @default.
• W2080883445 hasAuthorship W2080883445A5045629779 @default.
• W2080883445 hasAuthorship W2080883445A5048676751 @default.
• W2080883445 hasAuthorship W2080883445A5050558965 @default.
• W2080883445 hasAuthorship W2080883445A5051378203 @default.
• W2080883445 hasAuthorship W2080883445A5052353123 @default.
• W2080883445 hasAuthorship W2080883445A5067077344 @default.
• W2080883445 hasAuthorship W2080883445A5081257602 @default.
• W2080883445 hasAuthorship W2080883445A5081649988 @default.
• W2080883445 hasAuthorship W2080883445A5087649056 @default.

• next